After defeating Khalil Rountree last month at UFC 219 in his Octagon debut, rising UFC light heavyweight prospect Michal Oleksiejczuk has been flagged for a potential United States Anti-Doping Agency (USADA) violation stemming from an in-competition drug test in conjuction with his Dec. 30 bout, per a recent announcement by USADA officials.
Oleksiejczuk, 22, defeated Rountree via unanimous decision to push his current win streak to 10. The Polish youngster pulled off one of the biggest upsets on the UFC 219 card, but it now appears as if he had some outside help.
From the official USADA statement:
“The UFC organization was notified today that the U.S. Anti-Doping Agency (USADA) informed Michal Oleksiejczuk of a potential Anti-Doping Policy violation stemming from an in-competition sample collected in conjunction with his recent bout against Khalil Roundtree at UFC 219 in Las Vegas, Nevada on December 30, 2017.
“USADA, the independent administrator of the UFC Anti-Doping Policy, will handle the results management and appropriate adjudication of this case involving Oleksiejczuk, as it relates to the UFC Anti-Doping Policy and future UFC participation. Because the Nevada Athletic Commission was the regulatory body overseeing the fight in Las Vegas and has licensing jurisdiction over Oleksiejczuk, USADA will work to ensure that the Nevada Athletic Commission has the necessary information to determine its proper judgment of Oleksiejczuk’s potential anti-doping violation. Additional information will be provided at the appropriate time as the process moves forward.”
While Oleksiejczuk will have his opportunity to prove his innocence, or lack of knowingly taking a banned substance, USADA rarely gets it wrong. It’s really a shame, especially considering the UFC’s 205-pound division is in desperate need of fresh blood.
Stick with Mania for ongoing updates pertaining to Oleksiejczuk’s failed test.